Wei Huang

发表

Quantitative Chemotherapeutic Profiling of Gynecologic Cancer Cell Lines Using Approved Drugs and Bioactive Compounds

Emily M. Lee, Ruili Huang, Wei Zheng, 2018, Translational oncology.

Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen

Ruili Huang, Misha Itkin, Paul Shinn, 2016, Nature Medicine.

Neural stem cells for disease modeling and evaluation of therapeutics for infantile (CLN1/PPT1) and late infantile (CLN2/TPP1) neuronal ceroid lipofuscinoses

Wei Zheng, J. Marugan, E. Ottinger, 2018, Orphanet Journal of Rare Diseases.

Small Molecules Identified from a Quantitative Drug Combinational Screen Resensitize Cisplatin's Response in Drug-Resistant Ovarian Cancer Cells

Wei Zheng, M. Shen, Wei Sun, 2018, Translational oncology.

Clinical Manifestations, Monitoring, and Prognosis: A Review of Cardiotoxicity After Antitumor Strategy

Wei Huang, R. Xu, Yingkun Guo, 2022, Frontiers in Cardiovascular Medicine.

Terfenadine resensitizes doxorubicin activity in drug-resistant ovarian cancer cells via an inhibition of CaMKII/CREB1 mediated ABCB1 expression

Wei Sun, J. Braisted, N. Sima, 2022, Frontiers in Oncology.

Quantitative proteomics reveals the downregulation of GRB2 as a prominent node of F806-targeted cell proliferation network.

E. Li, Li-Yan Xu, Wei Jia, 2015, Journal of proteomics.

Macrolide analog F806 suppresses esophageal squamous cell carcinoma (ESCC) by blocking β1 integrin activation

E. Li, Li-Yan Xu, Wei Jia, 2015, Oncotarget.

Disease modeling for Mucopolysaccharidosis type IIIB using patient derived induced pluripotent stem cells.

Wei Zheng, M. Swaroop, Miao Xu, 2021, Experimental cell research.

An induced pluripotent stem cell line (TRNDi006-A) from a MPS IIIB patient carrying homozygous mutation of p.Glu153Lys in the NAGLU gene

Wei Zheng, Chengyu Liu, Miao Xu, 2019, Stem cell research.